Bionano Genomics (NASDAQ: BNGO) stock surged 7.02% in after-hours trading on Tuesday, following the release of the company's second-quarter 2024 financial results. Despite facing challenges in certain regions, the company reported several positive developments that fueled investor optimism.
One of the key highlights was the approval of a Category 1 CPT code for optical genome mapping, which is expected to significantly increase adoption and utilization of Bionano's technology. Additionally, the company's installed base of OGM systems grew by 29% year-over-year, reaching 363 systems, indicating strong demand for its products.
Bionano also reported a substantial reduction in operating expenses, with non-GAAP operating expenses decreasing by 46% compared to the same period in 2023. This cost-cutting measure, coupled with the potential revenue boost from the CPT code approval and new partnerships, such as the Software Marketing Agreement with Revvity, has bolstered investor confidence in the company's prospects.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。